keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer neoadjuvant treatment

keyword
https://www.readbyqxmd.com/read/29138989/sexual-function-and-sex-hormones-in-breast-cancer-patients
#1
Antonio Gambardella, Daniela Esposito, Giacomo Accardo, Marianna Taddeo, Antonietta Letizia, Rossella Tagliafierro, Katherine Esposito, Daniela Pasquali
PURPOSE: Breast cancer patients (BCP) are at risk of female sexual dysfunction (FSD). Our aim was to clarify the effects of treatment strategies, and steroid hormones levels on FSD. METHODS: We enrolled 136 BCP (46.9 ± 0.8 years), and 122 completed questionnaires. BCP were divided into four groups: 22 women with advanced breast cancer on neoadjuvant therapy (NAT), 48 on adjuvant therapy (AT), 30 taking hormonal therapy (HT) and 22 with metastatic cancer on first line chemotherapy (FLT)...
November 14, 2017: Endocrine
https://www.readbyqxmd.com/read/29138861/immunogenic-tumor-cell-death-induced-by-chemotherapy-in-patients-with-breast-cancer-and-esophageal-squamous-cell-carcinoma
#2
Keita Aoto, Kousaku Mimura, Hirokazu Okayama, Motonobu Saito, Shun Chida, Masaru Noda, Takahiro Nakajima, Katsuharu Saito, Noriko Abe, Shinji Ohki, Tohru Ohtake, Seiichi Takenoshita, Koji Kono
It has been reported that chemo-radiotherapy can induce immunogenic tumor cell death (ICD), which triggers T-cell immunity mainly mediated by high-mobility group box 1 protein (HMGB1) and calreticulin. However, there is still limited information to support this theory relating to chemotherapy alone. In the present study, the expression of HMGB1 and calreticulin was evaluated by immunohistochemistry in pre-treatment biopsy specimens and surgically resected specimens, which were obtained from patients with breast cancer (n=52) and esophageal squamous cell carcinoma (ESCC) (n=8) who had been treated with neoadjuvant chemotherapy (NAC)...
November 14, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29134191/assessing-treatment-response-in-triple-negative-breast-cancer-from-quantitative-image-analysis-in-perfusion-magnetic-resonance-imaging
#3
Imon Banerjee, Sadhika Malladi, Daniela Lee, Adrien Depeursinge, Melinda Telli, Jafi Lipson, Daniel Golden, Daniel L Rubin
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is sensitive but not specific to determining treatment response in early stage triple-negative breast cancer (TNBC) patients. We propose an efficient computerized technique for assessing treatment response, specifically the residual tumor (RT) status and pathological complete response (pCR), in response to neoadjuvant chemotherapy. The proposed approach is based on Riesz wavelet analysis of pharmacokinetic maps derived from noninvasive DCE-MRI scans, obtained before and after treatment...
January 2018: Journal of Medical Imaging
https://www.readbyqxmd.com/read/29132557/triple-negative-breast-cancer-who-should-receive-neoadjuvant-chemotherapy
#4
REVIEW
Lubna N Chaudhary, K Hope Wilkinson, Amanda Kong
Progress in the treatment of triple-negative breast cancer remains an important challenge. Given the aggressive biology and high risk of distant recurrence, systemic chemotherapy is warranted in most patients. Neaodjuvant chemotherapy benefits patients with locally advanced disease by downsizing the tumor and increasing the probability of breast-conserving surgery. Clinical and pathologic responses provide important prognostic information, which makes neoadjuvant therapy an attractive approach for all patients with triple-negative breast cancer...
January 2018: Surgical Oncology Clinics of North America
https://www.readbyqxmd.com/read/29132326/association-between-gene-expression-profile-of-the-primary-tumor-and-chemotherapy-response-of-metastatic-breast-cancer
#5
Cemile Dilara Savci-Heijink, Hans Halfwerk, Jan Koster, Marc Joan Van de Vijver
BACKGROUND: To better predict the likelihood of response to chemotherapy, we have conducted a study comparing the gene expression patterns of primary tumours with their corresponding response to systemic chemotherapy in the metastatic setting. METHODS: mRNA expression profiles of breast carcinomas of patients that later developed distant metastases were analyzed using supervised and non-supervised classification techniques to identify predictors of response to chemotherapy...
November 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29132268/simplifying-logistics-and-avoiding-the-unnecessary-in-patients-with-breast-cancer-undergoing-sentinel-node-biopsy-a-prospective-feasibility-trial-of-the-preoperative-injection-of-super-paramagnetic-iron-oxide-nanoparticles
#6
A Karakatsanis, H Olofsson, P Stålberg, L Bergkvist, S Abdsaleh, F Wärnberg
PURPOSE: Sentinel node is routinely localized with the intraoperative use of a radioactive tracer, involving challenging logistics. Super paramagnetic iron oxide nanoparticle is a non-radioactive tracer with comparable performance that could allow for preoperative localization, would simplify the procedure, and possibly be of value in axillary mapping before neoadjuvant treatment. The current trial aimed to determine the a priori hypothesis that the injection of super paramagnetic iron oxide nanoparticles in the preoperative period for the localization of the sentinel node is feasible...
November 1, 2017: Scandinavian Journal of Surgery: SJS
https://www.readbyqxmd.com/read/29127857/the-updated-network-meta-analysis-of-neoadjuvant-therapy-for-her2-positive-breast-cancer
#7
REVIEW
Ayako Nakashoji, Tetsu Hayashida, Takamichi Yokoe, Hinako Maeda, Tomoka Toyota, Masayuki Kikuchi, Rurina Watanuki, Aiko Nagayama, Tomoko Seki, Maiko Takahashi, Takayuki Abe, Yuko Kitagawa
BACKGROUND: We previously described a systematic assessment of the neoadjuvant therapies for human epidermal growth factor receptor-2 (HER2) positive breast cancer, using network meta-analysis. Accumulation of new clinical data has compelled us to update the analysis. METHODS: Randomized trials comparing different anti-HER2 regimens in the neoadjuvant setting were included, and odds ratio for pathologic complete response (pCR) in seven treatment arms were assessed by pooling effect sizes...
October 31, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29112227/trends-and-variations-in-postmastectomy-radiation-therapy-for-breast-cancer-in-patients-with-1-to-3-positive-lymph-nodes-a-national-cancer-data-base-analysis
#8
Nisha Ohri, Mark P Sittig, Chiaojung Jillian Tsai, Eun-Sil Shelley Hwang, Elizabeth Ann Mittendorf, Weiji Shi, Zhigang Zhang, Alice Y Ho
BACKGROUND: High-level evidence is lacking to guide treatment decisions about postmastectomy radiation therapy (PMRT) in patients who have breast cancer with 1 to 3 positive lymph nodes who receive contemporary systemic therapies, leading to potential variations in PMRT delivery. The objective of this study was to examine nationwide trends in PMRT use in this group. METHODS: The National Cancer Data Base (NCDB) was used to identify 93,372 women who had T1-T2N1 breast cancer diagnosed between 2003 and 2012...
November 7, 2017: Cancer
https://www.readbyqxmd.com/read/29110096/role-of-platinum-in-early-stage-triple-negative-breast-cancer
#9
REVIEW
Alyssa La Belle, Jude Khatib, William P Schiemann, Shaveta Vinayak
Triple-negative breast cancer (TNBC) is both a clinically and genomically heterogeneous disease, with distinct molecular subtypes; however, most epidemiologic and clinical studies to date have defined it under a "one disease" umbrella. This is an important point, since one therapeutic approach for all TNBCs is unlikely to be successful given the underlying biological diversity. In this review, we explore the role of platinums in the treatment of TNBC, as well as the potential for biomarkers to predict patient response to these agents...
November 6, 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/29108344/diffusion-weighted-mr-imaging-in-prediction-of-response-to-neoadjuvant-chemotherapy-in-patients-with-breast-cancer
#10
Xue-Ying Hu, Ying Li, Guan-Qiao Jin, Shao-Lv Lai, Xiang-Yang Huang, Dan-Ke Su
This study aims to evaluate the potential of apparent diffusion coefficient (ADC) derived from diffusion-weighted MR imaging for predicting the treatment response to neoadjuvant chemotherapy (NACT) in patients with breast cancer. Magnetic resonance imaging was performed prior to NACT and after two cycles of NACT. The correlation between mean ADCpre values, mean ADCpost values, changes in ADC values and changes in tumor diameters after NACT was examined using Spearman rank correlation. A total of 164 breast cancers were enrolled in this study...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29108309/weekly-paclitaxel-and-cisplatin-as-neoadjuvant-chemotherapy-with-locally-advanced-breast-cancer-a-prospective-single-arm-phase-ii-study
#11
Liheng Zhou, Shuguang Xu, Wenjin Yin, Yanpin Lin, Yueyao Du, Yiwei Jiang, Yaohui Wang, Jie Zhang, Ziping Wu, Jinsong Lu
There was little evidence of weekly cisplatin regimen either for the locally advanced breast cancer or the metastatic setting. We aimed to evaluate that whether the combination of weekly paclitaxel and cisplatin could improve the efficacy of the neoadjuvant treatment for patients with locally advanced breast cancer. Patients with histologically confirmed large operable breast cancer received paclitaxel 80mg/m(2) by weekly for 16 weeks and weekly cisplatin 25mg/m(2) on day 1, 8 and 15, out of every 28 days for 4-week cycles...
October 3, 2017: Oncotarget
https://www.readbyqxmd.com/read/29103853/adherence-to-adjuvant-endocrine-therapy-in-christchurch-women-with-early-breast-cancer
#12
B Robinson, B Dijkstra, V Davey, S Tomlinson, C Frampton
AIMS: To assess adherence to adjuvant endocrine therapy by a real-world cohort of women in Christchurch and to determine any associated factors. MATERIALS AND METHODS: Records were retrieved of all women newly diagnosed with early breast cancer and registered on the Christchurch Breast Cancer Patient Register over 4 years from June 2009. Demographic and pathological factors, dates of starting and stopping endocrine therapies and reported side-effects were collected...
November 2, 2017: Clinical Oncology: a Journal of the Royal College of Radiologists
https://www.readbyqxmd.com/read/29101985/acr-appropriateness-criteria-%C3%A2-monitoring-response-to-neoadjuvant-systemic-therapy-for%C3%A2-breast-cancer
#13
Priscilla J Slanetz, Linda Moy, Paul Baron, Roberta M diFlorio, Edward D Green, Samantha L Heller, Anna I Holbrook, Su-Ju Lee, Alana A Lewin, Ana P Lourenco, Bethany Niell, Ashley R Stuckey, Sunita Trikha, Nina S Vincoff, Susan P Weinstein, Monica M Yepes, Mary S Newell
Patients with locally advanced invasive breast cancers are often treated with neoadjuvant chemotherapy prior to definitive surgical intervention. The primary aims of this approach are to: 1) reduce tumor burden thereby permitting breast conservation rather than mastectomy; 2) promptly treat possible metastatic disease, whether or not it is detectable on preoperative staging; and 3) potentially tailor future chemotherapeutic decisions by monitoring in-vivo tumor response. Accurate radiological assessment permits optimal management and planning in this population...
November 2017: Journal of the American College of Radiology: JACR
https://www.readbyqxmd.com/read/29100977/evaluation-of-weekly-paclitaxel-plus-carboplatin-followed-by-anthracycline-chemotherapy-on-the-neoadjuvant-treatment-of-patients-with-triple-negative-breast-cancer
#14
Aurelio B Castrellon
OBJECTIVE: To evaluate the effectiveness and tolerability of neoadjuvant chemotherapy with weekly paclitaxel in combination with weekly carboplatin area under curve 2 followed by anthracycline chemotherapy. PATIENTS AND METHODS: This is a retrospective review of electronic medical records of patients (N = 32) with stage 1c-III triple-negative breast cancer. Patients received neoadjuvant chemotherapy with paclitaxel 80 mg/m(2) once per week for 12 weeks in combination with carboplatin area under curve 2 once per week for 12 weeks (wP + wCb), followed by a standard anthracycline regimen including either doxorubicin 60 mg/m(2) and cyclophosphamide 600 mg/m(2) every 2 or 3 weeks, or epirubicin 90 mg/m(2) and cyclophosphamide 600 mg/m(2) every 3 weeks for four cycles with myeloid growth factor support...
October 28, 2017: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/29096247/a-long-noncoding-rna-signature-that-predicts-pathological-complete-remission-rate-sensitively-in-neoadjuvant-treatment-of-breast-cancer
#15
Gen Wang, Xiaosong Chen, Yue Liang, Wei Wang, Kunwei Shen
BACKGROUND: Mounting evidence suggests that long noncoding RNAs (lncRNAs) are closely related to pathological complete response (pCR) in neoadjuvant treatment of breast cancer. Here, we construct lncRNA associated models to predict pCR rate. METHODS: LncRNA expression profiles of breast cancer patients treated with neoadjuvant chemotherapy (NAC) were obtained from Gene Expression Omnibus by repurposing existing microarray data. The prediction model was firstly built by analyzing the correlation between pCR and lncRNA expression in the discovery dataset GSE 25066 (n=488)...
October 27, 2017: Translational Oncology
https://www.readbyqxmd.com/read/29093602/fertility-preservation-in-female-patients-with-breast-cancer-a-current-overview
#16
Veronika Guenther, Ibrahim Alkatout, Wiebe Junkers, Dirk Bauerschlag, Nicolai Maass, Soeren von Otte
Many premenopausal patients who develop breast cancer have not yet completed their family planning, so measures of fertility protection to preserve their fertile potential would be beneficial. Polychemotherapy causes irreversible damage to the ovarian follicles - irrespective of whether in a neoadjuvant or adjuvant setting - and this can sometimes result in permanent infertility. Depending on which cytostatic agents are used and on the age-related ovarian reserve of the woman, gonadotoxic risk must be classified as low, moderate or high...
October 2017: Geburtshilfe und Frauenheilkunde
https://www.readbyqxmd.com/read/29089798/neoadjuvant-systemic-therapy-in-breast-cancer-use-and-trends-in-radiotherapy-practice
#17
T A Koulis, K Beecham, C Speers, S Tyldesley, D Voduc, C Simmons, R Olson
BACKGROUND: The use of neoadjuvant systemic therapy (nast) in the treatment of breast cancer is increasing, and the role of adjuvant radiation therapy (rt) in that setting is uncertain. We sought to review and report the use of nast, its trends over time, and its relationship with the prescribing patterns of locoregional rt in a provincial cancer system. METHODS: Patients with stages i-iii breast cancer diagnosed during 2007-2012 were identified using a provincial database...
October 2017: Current Oncology
https://www.readbyqxmd.com/read/29089281/influence-of-biologic-subtype-of-inflammatory-breast-cancer-on-response-to-neoadjuvant-therapy-and-cancer-outcomes
#18
Tina J Hieken, Brittany L Murphy, Judy C Boughey, Amy C Degnim, Katrina N Glazebrook, Tanya L Hoskin
BACKGROUND: Few data exist on the influence of tumor biologic subtype on treatment response and outcomes for inflammatory breast cancer (IBC). We examined a contemporary cohort of IBC patients treated with current targeted systemic therapies, selected on the basis of tumor biologic subtype, to evaluate pathologic treatment response and cancer outcomes across biologic subtypes. PATIENTS AND METHODS: We studied 57 clinical stage T4dM0 IBC patients operated on at our institution from October 2008 to July 2015...
October 7, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29080657/neoadjuvant-chemotherapy-for-breast-cancer-treatment-and-the-evidence-based-interaction-with-immediate-autologous-and-implant-based-breast-reconstruction
#19
REVIEW
Jordi Riba, Santiago Escriva de Romani, Jaume Masia
This article aims to determine the impact of neoadjuvant chemotherapy on immediate breast reconstruction by assessing their compatibility for oncological safety and the incidence and management of postoperative complications. A review of scientific publications published between 2009 and 2017 was undertaken. The relationship between neoadjuvant chemotherapy and immediate breast reconstruction was analyzed to compile and assess the potential interaction between the procedures. The search was limited to English language publications, but there were no limiting factors at the level of study typology...
January 2018: Clinics in Plastic Surgery
https://www.readbyqxmd.com/read/29077781/a-gene-signature-to-predict-high-tumour-infiltrating-lymphocytes-after-neoadjuvant-chemotherapy-and-outcome-in-patients-with-triple-negative-breast-cancer
#20
C Criscitiello, M A Bayar, G Curigliano, F W Symmans, C Desmedt, H Bonnefoi, B Sinn, G Pruneri, C Vicier, J Y Pierga, C Denkert, S Loibl, C Sotiriou, S Michiels, F André
INTRODUCTION: In patients with triple-negative breast cancer (TNBC), the extent of tumor-infiltrating lymphocytes (TILs) in the residual disease (RD) after neoadjuvant chemotherapy (NACT) is associated with better prognosis. Our objective was to develop a gene signature from pre-treatment samples to predict the extent of TILs after NACT, and then to test its prognostic value on survival. PATIENTS AND METHODS: Using 99 pre-treatment samples, we generated a four-gene signature associated with high post-NACT TILs...
October 25, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
keyword
keyword
105931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"